More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.06B
EPS
-0.31
P/E ratio
--
Price to sales
4.06
Dividend yield
--
Beta
0.639482
Previous close
$23.44
Today's open
$23.37
Day's range
$23.09 - $23.67
52 week range
$11.48 - $25.92
show more
CEO
Laura A. Francis
Employees
376
Headquarters
San Jose, CA
Exchange
NASDAQ Global Market
Shares outstanding
45113087
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Are You Looking for a Top Momentum Pick? Why Si-Bone (SIBN) is a Great Choice
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Nov 12, 2026

SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 11, 2026

SiBone (SIBN) Hit a 52 Week High, Can the Run Continue?
Si-Bone (SIBN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research • Nov 5, 2026

SiBone Q3 Earnings Call Highlights
SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building on momentum across its sacroiliac joint, complex spinal fusion and trauma offerings, while preparing for a broader launch of its newly cleared iFuse Granite Onyx platform.
MarketBeat • Nov 3, 2026

SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representing growth of 14.5% U.S. revenue of $52.8 million, representing growth of 13.9% Gross margin of 79.3% Net loss of $3.6 million, representing an improvement of 20.7% Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4% Positive cash from operations of $5.9 million, representing an improvement of 154.4% $146.3 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) 1,770 active U.S. physicians, representing growth of ~16% In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 2, 2026

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
Zacks Investment Research • Nov 2, 2026

SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference in Palm Beach Gardens, FL. Management will be hosting a fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
GlobeNewsWire • Oct 29, 2026

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire • Oct 19, 2026

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone
GlobeNewsWire • Sep 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell SI-BONE Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.